Sign In
Buy CORT
$72.65
+1.45 (+2.04%)
At Close: Jun 03, 2026
These 3 Biotech Stocks Are Outperforming Their Peers — Here's Why
02:00pm, Tuesday, 07'th Jul 2020
The best biotech companies to invest in tend to have a commonality: a strong streak of earnings growth.
Is Corcept Therapeutics Incorporated's(NASDAQ:CORT) Recent Stock Performance Tethered To Its Strong Fundamentals?
04:56pm, Monday, 06'th Jul 2020
Corcept Therapeutics''s (NASDAQ:CORT) stock is up by a considerable 49% over the past three months. Given that the...
State of Tennessee Treasury Department Trims Stock Position in Corcept Therapeutics Incorporated (NASDAQ:CORT)
09:34am, Sunday, 05'th Jul 2020
State of Tennessee Treasury Department cut its stake in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) by 18.2% in the 1st quarter, according to the company in its most recent filing with t
Corcept's Phase 3 Trial, And Other News: The Good, Bad And Ugly Of Biopharma
06:40am, Sunday, 05'th Jul 2020
Corcept starts its phase 3 pancreatic cancer trial. Ultragenyx gets approval for Dojolvi. Akero posts strong NASH data.
Invesco Ltd. Has $16.24 Million Stock Position in Corcept Therapeutics Incorporated (NASDAQ:CORT)
06:46am, Thursday, 02'nd Jul 2020
Invesco Ltd. decreased its position in Corcept Therapeutics Incorporated (NASDAQ:CORT) by 30.0% in the 1st quarter, Holdings Channel.com reports. The institutional investor owned 1,365,987 shares of t
Corcept Begins Enrollment in Phase III Pancreatic Cancer Study
02:47pm, Wednesday, 01'st Jul 2020
Corcept (CORT) enrolls the first patient in the phase III RELIANT study on relacorilant in combination with Abraxane for treating metastatic pancreatic cancer.
Corcept Therapeutics Initiates Phase 3 Trial of Relacorilant Plus Nab-Paclitaxel in Patients with Metastatic Pancreatic Cancer
08:05pm, Tuesday, 30'th Jun 2020
Corcept Therapeutics Incorporated (CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the
Corcept Therapeutics Incorporated (NASDAQ:CORT) Shares Bought by Thrivent Financial for Lutherans
07:30am, Friday, 26'th Jun 2020
Thrivent Financial for Lutherans grew its stake in Corcept Therapeutics Incorporated (NASDAQ:CORT) by 5.3% during the first quarter, according to the company in its most recent disclosure with the Sec
Victory Capital Management Inc. Has $940,000 Stake in Corcept Therapeutics Incorporated (NASDAQ:CORT)
06:39am, Friday, 26'th Jun 2020
Victory Capital Management Inc. grew its stake in Corcept Therapeutics Incorporated (NASDAQ:CORT) by 17.6% during the 1st quarter, according to its most recent 13F filing with the Securities and Excha
Janus Henderson Group PLC Reduces Stake in Corcept Therapeutics Incorporated (NASDAQ:CORT)
08:54am, Thursday, 25'th Jun 2020
Janus Henderson Group PLC lowered its holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT) by 70.0% during the 1st quarter, according to the company in its most recent filing with the Securitie
Legal & General Group Plc Acquires 954 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT)
06:56am, Thursday, 25'th Jun 2020
Legal & General Group Plc boosted its stake in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) by 0.3% during the 1st quarter, according to its most recent 13F filing with the SEC. The firm
Maha Govt Forms Task Force to Study Transport Service Issues in Wake of Pandemic
01:21pm, Wednesday, 24'th Jun 2020
Sources in transport department said the first meeting of the task force will be held at the office of transport commissioner in south Mumbai on June 26. Members can also join online.
Corcept Therapeutics (NASDAQ:CORT) Reaches New 52-Week High at $18.17
06:26am, Wednesday, 24'th Jun 2020
Corcept Therapeutics Incorporated (NASDAQ:CORT)’s stock price hit a new 52-week high during trading on Monday . The stock traded as high as $18.17 and last traded at $17.94, with a volume of 1154847
Corcept Therapeutics (NASDAQ:CORT) Lowered to “Hold” at Zacks Investment Research
06:26am, Wednesday, 24'th Jun 2020
Zacks Investment Research lowered shares of Corcept Therapeutics (NASDAQ:CORT) from a buy rating to a hold rating in a research note published on Tuesday morning, Zacks.com reports. The firm currently
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 23)
ACADIA Pharmaceuticals Inc...
